ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Malignant Solid Neoplasm|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Estrogen Receptor Positive|HER2/Neu Negative|Metastatic Malignant Solid Neoplasm|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Recurrent Breast Carcinoma|TP53 wt Allele|Unresectable Malignant Solid Neoplasm
Interventions: DRUG: MDM2/MDMX Inhibitor ALRN-6924|DRUG: Paclitaxel
Sponsor: M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)